PROGRAM:

Interactive Panel Discussion Focus: Partnering in the Biotech & Pharmaceutical Industry to Create Value & Competitive Advantage

Topics to be discussed:

• Analysis of Trends in BioPharma Alliances
• Roles of Business Development & Alliance Management in BioPharma
• Mechanics of Negotiating the Deal – from BD & AM viewpoints
• Due Diligence, Reasons to Walk Away, and Reasons to Compete for Deals
• Post-Deal Alliance Management Metrics
• Managing Complex (and sometime competitive) Partnerships

COST: 

Cost: ASAP members: $30 online, $40 at the door
Non-members: $40 online, $50 at the door
Entrance fee is also payable at the door by cash or bank car

REGISTER:

Online Registration http://www.acteva.com/go/ASAPMW
Online registrations must be received by noon on Tuesday April 11, 2006.

SPEAKER BIOS: 

Ian McKenna
Ian is a Canadian Chartered Accountant who started his career with Price Waterhouse Coopers in Montreal. He has held executive positions with industrial goods, cosmetics and investment management companies. Prior to joining Eli Lilly in 1988, he was the general manager of a plastic injection molding company in the automotive industry.

During his career at Lilly, Ian has been the financial director for various functions including Global Information Technology, Global Manufacturing, Research Technologies, Product Discovery and Development, as well as Regulatory and Medical. He was also the CFO for Lilly's start-up venture, Control Diabetes Services, in Dallas.

Ronald D. Henriksen

Ronald Henriksen joined Semafore Pharmaceuticals as Chairman and CEO in January, 2005. He is also Founder and Chief Investment Officer of Twilight Venture Partners, a closely- held Indianapolis life sciences venture fund.  Mr. Henriksen has over 30 years of experience in the pharmaceutical and biotechnology business, starting his life sciences career at Eli Lilly in 1970.  . He held U.S and International executive positions in finance, marketing and general management at Lilly. In 1982, he became Lilly's first Director of Business Development. In this role, Mr. Henriksen identified and negotiated 52 research and development collaborations with, or acquisitions of, biotechnology, diagnostic and medical device companies for Lilly. He was involved in the first partnership between Genentech and Lilly for human insulin; a deal that is considered to be the first biotechnology deal He also managed a $100+ million internal venture capital fund which made equity investments in more than twenty of these Lilly alliance partners.  In 1993, Mr. Henriksen became President and CEO of Khepri Pharmaceuticals, a California biopharmaceutical company developing innovative protease inhibitors, which he later sold to Arris Pharmaceuticals in late 1995. This combined company was later acquired by Celera Genomics.  From 1996 to 1998, Mr. Henriksen was CEO of Itasca Ventures, a Minneapolis life science incubator. Itasca was founded by Crescendo Ventures, Vanguard Venture Partners, Medtronic and Imation (3M) to create new medical device products and/or companies for later investment by the Partners. From 1999 to 2002, Mr. Henriksen served as the President and CEO of Indiana University Research and Technology Institute. IURTC owns and licenses all technology developed within I.U.

In addition to his Chairman's role at Semafore, Mr. Henriksen serves on the Boards of Directors of QLT, Inc. (QLTI, Vancouver), Cytori Therapeutics (CYTX, San Diego), IMI International Medical Innovations (Toronto), BioStorage Technologies, and ANGEL Learning (Indianapolis).

Mr. Henriksen received his BS in Industrial Administration from Iowa State University and an MBA (with distinction) from Harvard Business School. He also served as a Navy officer on Pacific Fleet ships for four years.

 
Harry Arader

Harry is President of The Centromere Group, a business consultancy specializing in biotechnology start-ups.  He is Co-Founder and VP, Business Operations of Nanodisc Inc., a "nano-biotech" start-up being spun out of the U of I Urbana.  In other Centromere Group projects, Mr. Arader acts as Business Development Consultant to Orion Genomics LLC, an epigenetics-based diagnostic company in St. Louis.  He serves as an outside director for Midway Pharmaceuticals, a new gastrointestinal drug company recently spun out from the University of Chicago.  He also served as Start-up CEO for BioDisplay Technologies Inc. which he sold to Abbott Laboratories in December 2001.   Through the Centromere Group, Mr. Arader has also served as a technology strategy consultant to many more established established life-science organizations including Monsanto, Unimed Pharmaceuticals (now Solvay), the University of Illinois, Argonne National Laboratory and to various governmental entities including the State of Illinois and Indiana's 21st Century Fund.  Earlier in his career, he was Chief Financial Officer of Millennium Pharmaceuticals Inc. which held its highly successful IPO during his time there.  Prior to Millennium he spent 10 years at Searle Pharmaceuticals as Managing Director of Searle Greater China; VP-International Marketing; and Executive Director-Strategic Planning among other roles.  Prior to Searle, Mr. Arader held positions in Sales and Marketing at Merck and Company. Mr. Arader did is undergraduate training in Anthropology at SUNY Purchase, and earned an MBA at The Wharton School in 1983.

Michael G. McCully

Mike McCully serves as a Director at Recombinant Capital (Recap), based in Walnut Creek, California. In his current capacity, Mike consults on deal structuring and valuation for Recap Consulting clients and focuses on top-level analyses of business development activity in the biotech and pharmaceutical industry. Recap Consulting clients include top tier pharmaceutical firms, investment concerns, and over thirty biotech companies, ranging from early stage platform companies to late stage drug developers. Recap's finger on the pulse of partnering in the drug industry serves as an invaluable tool to its clients. Over the past 15 years, Recap has been retained to assist in hundreds of biotech transactions with a total value to date of over $7 billion.

Prior to his joining Recap, Mike spent time working with Burrill & Company evaluating investment opportunities for the firm's venture funds and developing strategies for investments in the diagnostic space. Mike held research positions at Northwestern University and Purdue University before his transition into biotech business. Mike holds a BS from Purdue University and an MS from Northwestern University.

Mike is a contributing author to Signals Magazine and Lab to Wall Street, and has scientific publications in The Proceedings of the National Academy of Sciences, Plant Cell, and The Australian Journal of Plant Physiology. Mike is a member of the Steering Committee for BayBioNEST, a forum organized to foster entrepreneurship in the field of biotechnology in the San Francisco Bay Area.

MORE INFO:

For additional Program Information or you have a program for the Chicago chapter, contact Bill Davidson, phone: (312) 440-0581 or email mwprograms@strategic-alliances.org